肿瘤浸润淋巴细胞在乳腺癌中的研究进展

摘要

Breast cancer is a heterogeneous disease.The formation and progression of tumor and the sensitivity to treatment differs from patient to patient.In addition to the widely used molecular subtype,novel markers are needed to better personalize the treatment of breast cancer.Tumor infiltrating lymphocyte (TIL) have been consistently documented in breast cancer lesions especially in triple negative and human epidermal growth factor receptor-2 positive breast cancer.Several clinical trials have revealed that TIL are associated with prognosis and can predict therapeutic efficacy of special therapy.TIL could be divided to different subtypes including CD8 + TIL,CD4 + TIL,cytotoxic T lymphocyte-associated antigen--4 + TIL,programmed death-1 + TIL.They play different roles in the process of anti-tumor immunity and can predict different prognosis.Screening out special TIL subtype which is well associated with prognosis and therapeutic efficacy and developing targeting immunotherapy can help to improve outcomes of breast cancer patients.%乳腺癌是一种高度异质性的肿瘤,不同乳腺肿瘤对治疗的反应及预后具有很大的差别.除外目前的分子分型系统,需进一步寻找更好的预后及疗效预测指标,指导乳腺癌的个体化治疗.目前研究发现,肿瘤浸润淋巴细胞(TIL)浸润程度在不同乳腺癌病灶中差异较大,三阴性与人类表皮生长因子受体2阳性乳腺癌病灶中TIL浸润程度较高.多项临床研究结果表明,TIL浸润程度与患者的预后及对特定治疗的反应性相关,可用于指导乳腺癌进一步临床分型.TIL尚能细分为CD8+、CD4+、细胞毒性T淋巴细胞抗原4阳性、程序性死亡受体1阳性等不同亚型,其在肿瘤免疫中的作用不同,具有不同的预测效能.如能筛选出与预后或特定治疗疗效相关的特定表型TIL亚群,并研制相应的免疫靶向治疗药物,可进一步提高乳腺癌患者的预后.